Recent studies revealed that a substantial proportion of patients with high-risk B-cell
precursor acute lymphoblastic leukemia (BCP-ALL) harbor fusions involving tyrosine kinase …

Approximately 15% of pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL) is
characterized by gene expression similar to that of BCR-ABL1-positive disease and …

Genetic alterations of Ikaros family zinc finger protein 1 (IKZF 1), point mutations in Janus
kinase 2 (JAK 2), and overexpression of cytokine receptor‐like factor 2 (CRLF 2) were …

Background ABL-class fusion genes other than BCR–ABL1 have been identified in
approximately 3% of children with newly diagnosed acute lymphocytic leukaemia, and …

ABL-class fusions other than BCR-ABL1 characterize around 2–3% of precursor B-cell acute
lymphoblastic leukemia. Case series indicated that patients suffering from these subtypes …

Activating tyrosine kinase mutations or cytokine receptor signalling alterations have attracted
attention as therapeutic targets for high‐risk paediatric acute lymphoblastic leukaemia (ALL) …

The EBF1-PDGFRB gene fusion accounts for< 1% of B-cell precursor acute lymphoblastic
leukemia (ALL) cases and occurs within the Philadelphia-like ALL subtype. We report 15 …

Recurrent chromosomal rearrangements carry prognostic significance in pediatric B-lineage
acute lymphoblastic leukemia (B-ALL). Recent genome-wide analyses identified a high-risk …

One recently identified subtype of pediatric B-precursor acute lymphoblastic leukemia (ALL)
has been termed BCR-ABL1–like or Ph-like because of similarity of the gene expression …

Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has achieved an 80%
cure rate as a result of a risk-adapted therapy largely based on minimal residual disease …